Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer

Head and Neck

Volumn 33, Issue 10, 2011, Pages 1394-1399

  Li, Pingdong ^a,b   Chen, Chun Hao ^a   Li, Sen ^a   Givi, Babak ^a   Yu, Zhenkun ^b   Zamarin, Dmitriy ^c   Palese, Peter ^c   Fong, Yuman ^a   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

head and neck cancer; Newcastle disease virus; oncolysis; viral therapy

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; GREEN FLUORESCENT PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY;

EID: 80053007260     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21609     Document Type: Article

References (15)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
4. Mullen JT, Tanabe KK,. Viral oncolysis. Oncologist 2002; 7: 106-119.
5. Wheelock EF, Dingle JH,. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N Engl J Med 1964; 271: 645-651.
6. Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992; 52: 448-453.
7. Lorence RM, Reichard KW, Katubig BB, et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 1994; 86: 1228-1233.
8. Cassel WA, Murray DR,. Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Reg 1988; 7: 351-352.
9. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69-77.
10. Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P,. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 2006; 103: 8203-8208.
11. Vigil A, Park MS, Martinez O, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007; 67: 8285-8292.
12. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y,. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001; 193: 12-21.
13. Yu Z, Li S, Brader P, Chen N, et al. Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer 2009; 8: 45.
14. Zamarin D, Vigil A, Kelly K, Garcia-Sastre A, Fong Y,. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009; 16: 796-804
15. Zamarin D, Martinez-Sobrido L, Kelly K, et al. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009; 17: 697-706.